



New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.

Diabetes Care 2020;43:e170–e171 | <https://doi.org/10.2337/dc20-1551>

Rebecca Unsworth,¹ Susan Wallace,²
Nick S. Oliver,¹ Shunmay Yeung,^{3,4}
Archana Kshirsagar,² Harshini Naidu,⁵
Ruth Min Wai Kwong,⁶ Priya Kumar,⁶
and Karen M. Logan⁴

Data on new-onset type 1 diabetes during the coronavirus disease 2019 (COVID-19) pandemic, particularly in children, are limited. A recent U.S. multicenter study reported outcomes in 64 adults and children with type 1 diabetes, and confirmed or suspected COVID-19. However, only six patients presented with new-onset type 1 diabetes (1).

We report multicenter regional data from North West London (NWL) of new-onset type 1 diabetes and diabetic ketoacidosis (DKA) in children up to the age of 16 years during the peak of the COVID-19 pandemic. We collected data from five inpatient units (four National Health Service [NHS] Trusts) comprising the NWL Pediatric Diabetes Network between 23 March (coinciding with the commencement of the U.K. Government lockdown) and 4 June 2020.

Thirty children aged 23 months to 16.8 years presented with new-onset type 1 diabetes (Table 1). We observed an apparent increase in two units, with 10 cases each (versus typically 2 and 4 cases, respectively, for April/May combined in the previous 5 years). Rates in the other three units were similar to previous years.

A high proportion of children (21/30, 70%) presented with DKA, with severe DKA (pH range 6.82–7.05) in over half (11/21, 52%). Twelve children presented with clinical shock and four were managed in pediatric intensive care. Two children presented with reduced conscious level, one received hyperosmolar therapy, and both recovered without complications. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR was performed from nasopharyngeal swabs in 21 children meeting local testing criteria; two tested positive. SARS-CoV-2 serum IgG antibody was tested in a subgroup of children attending one of two units; 3 of 16 children (19%) tested positive. Of the five children with positive results, three presented with severe DKA and refractory hypokalemia, and one child with positive SARS-CoV-2 PCR suffered a hypokalemia-related cardiac arrest but recovered fully following 1 day of ventilation. Only three children with known type 1 diabetes presented with DKA during the same time period.

In comparison with a typical year, we estimate this represents an additional

12–15 new type 1 diabetes cases (80% increase) during the COVID-19 pandemic, with apparent clusters of cases observed in two units. The angiotensin converting enzyme 2 (ACE2) receptor is the binding site for SARS-CoV-1 and -2 (2) and is strongly expressed in pancreatic endocrine cells (3). Previous evidence suggests that SARS-CoV-1 virus may have entered pancreatic islet cells via the ACE2 receptor leading to β -cell damage and new-onset, mainly transient diabetes (3). While our data do not prove a link, we postulate that SARS-CoV-2 exposure contributed to the observed increase in cases by precipitating or accelerating type 1 diabetes onset.

Reports from China and Italy describe a number of children presenting with new-onset type 1 diabetes or severe DKA during the COVID-19 pandemic, apparently unrelated to infection (4). This prompted concerns of delayed presentation, but we suggest that a number of these cases may be attributed to prior SARS-CoV-2 exposure. In accordance with previous reports, we observed a high rate of severe DKA, but delayed presentation did

¹Imperial College London, London, U.K.

²Chelsea and Westminster NHS Foundation Trust, London, U.K.

³London School of Hygiene & Tropical Medicine, London, U.K.

⁴St Mary's Hospital, Imperial College Healthcare NHS Trust, London, U.K.

⁵The Hillingdon Hospitals NHS Foundation Trust, Uxbridge, U.K.

⁶London North West University Healthcare NHS Trust, London, U.K.

Corresponding author: Karen M. Logan, k.logan@imperial.ac.uk

Received 23 June 2020 and accepted 25 June 2020

R.U. and S.W. are joint first authors.

This article is part of a special article collection available at <https://care.diabetesjournals.org/collection/diabetes-and-COVID19>.

© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

See accompanying articles, pp. 2631, 2870, and e172.

Table 1—Children presenting with new-onset type 1 diabetes or with DKA and known type 1 diabetes

	New onset type 1 diabetes (<i>n</i> = 30)					Known type 1 diabetes with DKA (<i>n</i> = 3)§
	All patients (<i>n</i> = 33)	SARS-CoV-2 not tested/negative* (<i>n</i> = 25)		SARS-CoV-2 PCR or IgG positive (<i>n</i> = 5)		
		Not in DKA (<i>n</i> = 8, 32%)	DKA (<i>n</i> = 17, 68%)	Not in DKA (<i>n</i> = 1, 20%)†	DKA (<i>n</i> = 4, 80%)‡	
Median age (IQR), years	10.9 (6.8)	12.0 (6.0)	10.3 (6.2)	5.8	11.6 (1.7)	13.2 (2.3)
Male	22 (68)	6 (75)	11 (65)	0 (0)	3 (75)	2 (67)
Median weight for age z score (IQR)	0.12 (1.44)	0.90 (2.09)	0.04 (1.62)	−0.23	0.96 (1.61)	0.12 (0.44)
Ethnicity						
White European	12 (36)	3 (38)	7 (41)	0 (0)	2 (50)	0 (0)
Black African	8 (24)	2 (25)	4 (24)	0 (0)	1 (25)	1 (33)
Arab	6 (18)	1 (13)	3 (18)	1 (100)	1 (25)	0 (0)
Asian	3 (9)	1 (13)	2 (12)	0 (0)	0 (0)	0 (0)
Other	4 (12)	1 (13)	1 (6)	0 (0)	0 (0)	2 (67)
Family history of type 1 diabetes	11 (33)	6 (75)	4 (24)	1 (100)	0 (0)	0 (0)
Comorbidities	2 (6)	1 (13)	1 (6)	0 (0)	0 (0)	0 (0)
Median duration of symptoms (IQR), days	7 (10)	14 (17)	7 (7)	10	10 (10)	1 (2)
Median plasma glucose on presentation (IQR), mg/dL	432 (200)	354 (155)	465 (177)	475	484 (135)	427 (87)
HbA _{1c} median, % (mmol/mol)	11.6 (103)	11.2 (99)	11.6 (103)	11.3 (100)	12.5 (113)	10.0 (86)
Median pH on presentation (IQR)	7.19 (0.28)	7.37 (0.06)	7.14 (0.29)	7.42	6.90 (0.08)	7.24 (0.11)
Severe DKA (pH <7.1)	12 (36)	—	8 (47)	—	3 (75)	1 (33)
Median plasma lactate on presentation (IQR), mmol/L	1.9 (2.5)	1.0 (0.04)	2.1 (2.3)	1.5	4.6 (0.8)	1.3

Data are *n* (%) unless otherwise indicated. IQR, interquartile range. *Eight children had no testing, six had SARS-CoV-2 PCR testing only, two had SARS-CoV-2 IgG testing only, nine had both SARS-CoV-2 PCR and IgG. †Positive for SARS-CoV-2 IgG. ‡Two positive for SARS-CoV-2 PCR and two positive for SARS-CoV-2 IgG. §One child had no testing, two children had negative SARS-CoV-2 PCR testing only.

not appear to be a significant factor, with relatively short symptom duration in the majority of children.

SARS-CoV-2 also affects the renin-angiotensin-aldosterone system through reduced ACE2 expression, leading to decreased degradation of angiotensin II and increased secretion of aldosterone and renal potassium loss (5). Although hypokalemia is not uncommon during treatment of DKA, particularly in cases of renal impairment, it is possible that reduction in ACE2 expression may have contributed in the reported cases.

Five children tested positive for SARS-CoV-2 PCR or IgG, but testing was not universal across NWL, and 14 children did not have SARS-CoV-2 IgG testing. This limited our ability to identify possible cases, particularly in children with recent suspected symptoms or known COVID-19 contacts. In addition, SARS-CoV-2 serology was tested soon after diagnosis and did not report IgM, and as antibody responses may not develop until 14–21 days postinfection, further cases may have been missed.

To the best of our knowledge, this is the first report to describe an apparent increase in new-onset type 1 diabetes in children during the COVID-19 pandemic, with evidence of SARS-CoV-2 infection or exposure in a proportion of those tested. Our intention is to raise awareness of a possible link between SARS-CoV-2 and new-onset type 1 diabetes, especially as there are reports of incident type 1 diabetes occurring as apparently small localized outbreaks. Further studies are required to establish a definitive link and any possible impact on the severity of type 1 diabetes presentation, including severe hypokalemia.

Acknowledgments. The authors thank Nicola Bridges and Bianca Parau (Chelsea and Westminster NHS Foundation Trust) and Jaikummar Ganapathi (The Hillingdon Hospitals NHS Foundation Trust) for their assistance with the data acquisition.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. N.S.O., S.Y., A.K., and K.M.L. conceived and designed the study. R.U., S.W., and K.M.L. acquired, analyzed, and interpreted data and drafted the manuscript. H.N.,

R.M.W.K., and P.K. acquired data. K.M.L. supervised the study. All authors reviewed and approved the final version of the manuscript. R.U., S.W., and K.M.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U.S. *Diabetes Care* 2020;43:e83–e85
2. Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target—a perspective. *Endocr Metab Immune Disord Drug Targets* 2020;20:807–811
3. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetol* 2010;47:193–199
4. International Society of Pediatric and Adolescent Diabetes (ISPAD). Summary of recommendations regarding COVID-19 in children with diabetes: Keep Calm and Mind your Diabetes Care and Public Health Advice. *Pediatr Diabetes* 2020;21:413–414
5. Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: the conundrum. *Diabetes Res Clin Pract* 2020;162:108132